Procter & Gamble (PG)
(Delayed Data from NYSE)
$175.90 USD
+1.38 (0.79%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $175.86 -0.04 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$175.90 USD
+1.38 (0.79%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $175.86 -0.04 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Zacks News
Procter & Gamble (PG) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
PG reported core earnings of $1.00 per share, beating the Zacks Consensus Estimate of 98 cents.
Should Investors Avoid Procter & Gamble (PG) Ahead of Earnings?
by Benjamin Rains
Shares of Procter & Gamble (PG) are down roughly 13% over the last year as the consumer packaged goods giant faces tougher competition from rivals and upstarts. With that said, earnings season could give Procter & Gamble a much needed shot in the arm, if it impresses investors.
Top Research Reports for Johnson & Johnson, Intel and Procter & Gamble
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Intel (INTC) and Procter & Gamble (PG).
Why Is Procter & Gamble (PG) Down 9% Since its Last Earnings Report?
by Zacks Equity Research
Procter & Gamble (PG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Value Investors Pick Procter & Gamble (PG) Stock Now?
by Zacks Equity Research
Let's see if The Procter & Gamble Company (PG) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Procter & Gamble (PG) Q2 Earnings & Revenues Top
by Zacks Equity Research
Procter & Gamble (PG) reported core earnings of $1.19 per share in Q2, beating the Zacks Consensus Estimate of $1.15/share.
How Procter & Gamble's (PG) Margins Will Shape Up in Q2
by Zacks Equity Research
Higher input cost, unfavorable mix and lower pricing in the shave care category likely hit Procter & Gamble's (PG) margins. However, the negatives might partly get offset by productivity savings.
Will New Products Lift Procter & Gamble's (PG) Q2 Sales?
by Zacks Equity Research
Soft consumer-spending environment and higher competition in developed markets might hurt Procter & Gamble's (PG) Q2 sales. However, new product launches are likely to offset the negatives.
Top Analyst Reports for Alphabet, Broadcom and Procter & Gamble
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Broadcom (AVGO) and Procter & Gamble (PG).
Factors to Weigh on Consumer Staples Stocks in 2018
by Zacks Equity Research
Responding to consumers' rapidly changing preferences creates significant competition, price wars and an intense promotional environment.
Clorox Hits 52-Week High: Will the Uptrend Continue in 2018?
by Zacks Equity Research
Clorox (CLX) has emerged as a sound investment opportunity supported by robust strategic initiatives, brand strength and 2020 Strategy.
Top Analyst Reports for Wal-Mart, Procter & Gamble and NVIDIA
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wal-Mart (WMT), Procter & Gamble (PG) and NVIDIA (NVDA).
Procter & Gamble Appoints Peltz to Board After Proxy Battle
by Zacks Equity Research
Co-founder of Trian Fund Management, Nelson Peltz has been appointed to Procter & Gamble's (PG) board, effective Mar 1, 2018.
Procter & Gamble (PG) Tops Q1 Earnings & Revenues
by Zacks Equity Research
The Procter & Gamble Company (PG) reported core earnings of $1.09 per share, beating the Zacks Consensus Estimate of $1.07/share.
Should You Buy The Procter & Gamble (PG) Ahead of Earnings?
by Zacks Equity Research
The Procter & Gamble (PG) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Will Near-Term Challenges Mar Whirlpool's (WHR) Q3 Earnings?
by Zacks Equity Research
Whirlpool Corp. (WHR) is slated to release third-quarter 2017 results on Oct 23, after the closing bell. Last quarter, the company posted a negative earnings surprise of 6.9%.
Will V.F. Corp (VFC) Strategies Facilitate Q3 Earnings Beat?
by Zacks Equity Research
We expect the designer, manufacturer and marketer of branded apparel and related products, V. F. Corporation (VFC) to beat expectations when it reports third-quarter 2017 results on Oct 23.
Top Ranked Income Stocks to Buy for October 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 16th:
Is a Beat in the Cards for SUPERVALU (SVU) in Q2 Earnings?
by Zacks Equity Research
SUPERVALU (SVU) is likely to beat earnings estimates in second-quarter fiscal 2018. The company remains committed to its wholesale operations.
Top Stock Reports for Procter & Gamble, PetroChina & Biogen
by Zacks Equity Research
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), PetroChina (PTR) and Biogen (BIIB)
Top Stock Reports for Procter & Gamble, PetroChina & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), PetroChina (PTR) and Biogen (BIIB).
Will Colgate's Strategic Initiatives Help Counter Sales Woes?
by Zacks Equity Research
Colgate-Palmolive (CL) remains committed to its savings programs with a disciplined capital strategy. However, the company has a dismal sales trend.
In The Wake Of The Carnage
by Zacks Equity Research
In The Wake Of The Carnage
In The Wake Of The Carnage
by Zacks Equity Research
In The Wake Of The Carnage
Can Colgate's (CL) Strategies Regain the Stock Momentum?
by Zacks Equity Research
Colgate-Palmolive Company (CL) has been witnessing soft sales due to continued softness in North America and challenges in Asia-Pacific region. However, management remains on track to deliver growth.